Maximo F. Nougues - 05 Jul 2022 Form 4/A - Amendment Insider Report for PUMA BIOTECHNOLOGY, INC. (PBYI)

Role
Chief Financial Officer
Signature
/s/ Gordon Esplin as attorney-in-fact for Maximo F. Nougues
Issuer symbol
PBYI
Transactions as of
05 Jul 2022
Net transactions value
-$24,547
Form type
4/A - Amendment
Filing time
04 Aug 2022, 21:30:44 UTC
Date Of Original Report
07 Jul 2022
Previous filing
06 Jun 2022
Next filing
04 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PBYI Common Stock Sale $24,547 -9,328 -7.7% $2.63 111,738 05 Jul 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Remarks:

On July 7, 2022, the Reporting Person filed a Form 4 which inadvertently reported that 5,835 shares of Common Stock were disposed in the transaction, following which a total of 64,625 shares of Common Stock were beneficially owned by the Reporting Person. In fact, as reported in this amendment, the Reporting Person disposed of 9,328 shares of Common Stock, following which the Reporting Person directly owned 111,738 shares of Common Stock.